Mid Cap Volatile Stocks: Ubiquiti Networks (NASDAQ:UBNT), Qunar Cayman Islands (NASDAQ:QUNR), Criteo (NASDAQ:CRTO), Intercept Pharmaceuticals (NASDAQ:ICPT)

Stock analysts at Macquarie initiated coverage on shares of Ubiquiti Networks Inc (NASDAQ:UBNT) in a report issued on Thursday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock. Ubiquiti Networks Inc (NASDAQ:UBNT) stock performance was -10.22% in last session and finished the day at $44.18. Traded volume was 2.87million shares in the last session and the average volume of the stock remained 1.34million shares. Ubiquiti Networks Inc (NASDAQ:UBNT) insider ownership is 0.50%.

Macquarie assumed coverage on shares of Qunar Cayman Islands Ltd (NASDAQ:QUNR) in a report issued on Monday, TheFlyOnTheWall.com reports. The firm issued a neutral rating and a $30.00 target price on the stock. Qunar Cayman Islands Ltd (NASDAQ:QUNR) dropped -7.67 percent to $26.83 Wednesday on volume of 1.22million shares. The intra-day range of the stock was $26.76 to $29.66. Qunar Cayman Islands Ltd (NASDAQ:QUNR) has a market capitalization of $3.02billion.

Criteo SA (ADR) (NASDAQ:CRTO) has set the price of its 5,250,000 American Depository Shares (ADSs), each representing one of Criteo SA (ADR) (NASDAQ:CRTO)’s ordinary shares, to the public at $45.00 per share. Criteo SA (ADR) (NASDAQ:CRTO)’s stock on Mar 26, 2014 reported a decrease of -12.34% to the closing price of $40.34. Its fifty two weeks range is $28.27 -$60.95. The total market capitalization recorded $2.32billion. The overall volume in the last trading session was 730.1K shares. In its share capital, CRTO has 53.28million outstanding shares.

In March 2014, the officers of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) named in the table below entered into pre-arranged stock trading plans pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). On Wednesday, shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) dropped -8.11% to close the day at $322.32. Company return on investment (ROI) is -47.90% and its monthly performance is recorded as -14.97%. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) quarterly revenue growth is 405.52%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone